An improved synthesis of haloacetamidine-based inactivators of protein arginine deiminase 4 (PAD4)
Authors:
- Paul R. ThompsonPTPaul R. Thompson
- 1 July 2008
- journal article
- research article
- Published by Elsevier in Tetrahedron Letters
- Vol. 49 (28) , 4383-4385
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- PADI4 polymorphisms and rheumatoid arthritis susceptibility: a meta-analysisRheumatology International, 2007
- Proteomics Implicates Peptidyl Arginine Deiminase 2 and Optic Nerve Citrullination in Glaucoma PathogenesisInvestigative Ophthalmology & Visual Science, 2006
- Modulation of Peptidyl Arginine Deiminase 2 and Implication for NeurodegenerationCurrent Eye Research, 2006
- A functional haplotype of thePADI4gene associated with increased rheumatoid arthritis susceptibility in KoreansArthritis & Rheumatism, 2005
- Expression of peptidylarginine deiminase type 4 (PAD4) in various tumorsMolecular Carcinogenesis, 2005
- Abnormal accumulation of citrullinated proteins catalyzed by peptidylarginine deiminase in hippocampal extracts from patients with Alzheimer's diseaseJournal of Neuroscience Research, 2005
- Citrullinated proteins: sparks that may ignite the fire in rheumatoid arthritisArthritis Research & Therapy, 2004
- PAD, a growing family of citrullinating enzymes: genes, features and involvement in diseaseBioEssays, 2003
- Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritisNature Genetics, 2003
- Peptidylarginine deiminase: a candidate factor in demyelinating diseaseJournal of Neurochemistry, 2002